地舒单抗治疗输血依赖型地中海贫血骨质疏松:随机、安慰剂对照、双盲2b期临床试验
该随机、安慰剂对照、双盲2b期试验评估地舒单抗(DNM)对输血依赖型地中海贫血(TDT)骨质疏松的疗效,患者分别接受60 mg DNM(n=32)或安慰剂(n=31)皮下注射,第0天和第180天给药,随访12个月。DNM组L1-L4骨密度增幅高于安慰剂组(5.92%±5.25% vs 2.92%±5.56%,P=.043),腕部骨密度优势更明显(-0.26%±5.31% vs -3.92%±8.71%,P=.035),未观察到3级或4级毒性。
要点
- DNM组L1-L4骨密度增幅5.92%±5.25%,高于安慰剂组2.92%±5.56%(P=.043)。
- DNM组腕部骨密度变化-0.26%±5.31%,优于安慰剂组-3.92%±8.71%。
- DNM降低疼痛评分,安慰剂组疼痛评分无变化。
核心结论
- DNM增加腰椎和腕部骨密度,降低疼痛和骨转换标志物,是管理TDT诱导的骨质疏松的又一有价值选择。
研究设计与样本
- 随机、安慰剂对照、双盲2b期临床试验,患者接受60 mg DNM(n=32)或安慰剂(n=31)皮下注射,第0天和第180天给药,随访12个月。
主要发现
- L1-L4骨密度增幅DNM组5.92%±5.25% vs 安慰剂组2.92%±5.56%(P=.043)。
- 腕部骨密度变化DNM组-0.26%±5.31% vs 安慰剂组-3.92%±8.71%(P=.035)。
- 未观察到3级或4级毒性。
- DNM降低疼痛评分,安慰剂组疼痛评分无变化。
- DNM组第12个月较基线可溶性RANKL、sRANKL/骨保护素比值、I型胶原C端肽、抗酒石酸酸性磷酸酶5b亚型及骨特异性碱性磷酸酶显著降低(所有比较P<.01),dickkopf-1、硬化蛋白和骨钙素无变化;安慰剂组研究期间上述指标升高(所有比较P<.01)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)-induced osteoporosis are rather limited. Thus, we conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density was much higher compared with placebo (-0.26% ± 5.31% vs -3.92% ± 8.71%, respectively; P = .035). No grade 3 or 4 toxicity was observed. DNM reduced pain scores that remained unaltered in the placebo group. DNM showed a significant reduction of soluble RANKL (sRANKL), sRANKL/osteoprotegerin ratio, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase between baseline and the 12th month (P < .01 for all comparisons) without changes in dickkopf-1, sclerostin, and osteocalcin. On the contrary, placebo patients showed an increase in sRANKL, osteoprotegerin, dickkopf-1, sclerostin, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase during the study period (P < .01 for all comparisons). In conclusion, DNM increased lumbar spine and wrist bone mineral density and reduced pain and bone remodeling markers, and thus it is another valuable option for the management of TDT-induced osteoporosis. This trial was registered at www.clinicaltrials.gov as #NCT02559648.
引用
- Voskaridou E, Ntanasis-Stathopoulos I, Papaefstathiou A, et al. Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial. Blood Adv. 2018. PMID: 30381400. doi:10.1182/bloodadvances.2018023085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。